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Introduction
The clinical potential of gene therapy has yet to be realized. Progress in this field would be greatly facilitated by the availability of targetable injectable vectors capable of efficient in vivo gene delivery to specific target cell types or to specific locations of disease pathology. Efforts to develop retroviral vectors capable of efficient targeted gene delivery are therefore a high priority in gene therapy research.
Retroviral vector targeting strategies can be divided into two broad categories. 1 In the first, the host range of the vector is extended, usually by incorporating a new receptor binding domain into the viral envelope, to allow it to infect nonpermissive cells that lack the viral receptor. Attempts to target gene delivery by host range extension have met with limited success because the efficiency of gene delivery to the targeted cells is often severely compromised.
2-5 However, there are exceptions to this rule. 6 Other targeting strategies fall into the general category of host range restriction in which the target cells are fully permissive for the unmodified vector and the targeting modifications serve primarily to restrict infection of nontarget cells. An advantage of targeting by host range restriction is that, because the natural virus entry pathway is exploited, efficient transduction of the target cells is more readily achieved.
Retroviral attachment and entry are mediated by homotrimeric viral envelope glycoproteins in which each subunit of the trimer comprises a transmembrane anchor component (TM) which is noncovalently linked to a larger, entirely extraviral glycoprotein component (SU). [7] [8] [9] The N-terminal domain of SU mediates attachment to the By fusing various polypeptides to the N-terminus of the retroviral envelope glycoprotein (SU), we have been able to demonstrate the feasibility of retroviral targeting strategies based on the principle of host range restriction. 10 A particularly promising approach has been to fuse inhibitory polypeptides to the N-terminus of SU through a protease-cleavable linker such that exposure to the relevant protease cleaves the inhibitory polypeptide from the vector, thereby restoring infectivity. [11] [12] [13] [14] [15] Two different types of polypeptide have been exploited as inhibitory adapters to provide the basis for protease targeting strategies. Thus, high affinity growth factor receptor binding domains (such as epidermal growth factor, insulin growth factor and stem cell factor) displayed on retrovirus envelopes can block gene delivery into receptor-positive target cells, presumably by sequestering the virus on to cell surface receptors that are unable to support subsequent steps in virus entry. Alternatively, when trimeric polypeptides (such as the Cterminal domain of CD40 ligand) are displayed at the Nterminus of the SU glycoprotein there is considerable steric impedance to virus attachment and entry such that infectivity is blocked on all target cells, irrespective of their receptor phenotype. 16 In either case, judiciously placed protease cleavage signals can be used to render the vectors susceptible to activation by specific proteases, a principle that has been convincingly demonstrated for a number of different target proteases including factor Xa, 11 plasmin, 14 matrix-metalloproteinases (MMPs) 12 and intracellular proprotein convertases. 17 A particularly attractive application of these protease targeting strategies would be to target gene delivery in vivo using vectors whose infectivity is dependent upon contact with membrane-associated proteases that are preferentially expressed on the surface of the targeted cells. We previously made epidermal growth factor (EGF)-displaying retroviral vectors whose infectivity on EGF receptor (EGFR)-expressing cells was conditional upon the presence of abundant endogenously produced MMPs, 12, 18 that established the feasibility of generating retroviral vectors that could be activated by disease-associated proteases. In the current study we sought to establish the true potential of protease-activatable vectors for targeting MMP-rich cells in a heterogeneous population and for targeting MMP-rich lesions in vivo. We found that the previously described MMP-activatable vector and a newly constructed trimer-displaying MMP-activatable vector could efficiently discriminate between MMP-rich and MMP-poor cells in a heterogeneous population. Moreover, selective transduction of MMP-rich tumor xenografts by the MMP-activatable vectors was convincingly demonstrated.
Results

Chimeric envelopes
The chimeric envelope constructs are shown diagramatically in Figure 1 . Two different polypeptides (EGF residues 1-53 or CD40 ligand residues 116-261) were fused to the N-terminus of the 4070A amphotropic envelope through two different linkers, one susceptible to cleavage by MMPs, and the other resistant to protease attack. The chimeric envelopes were incorporated into ␤-galactosidase transducing retroviral vectors by stably expressing them in TELCeB.6 cells which produce abundant envelope-deficient (hence non-infectious) vector particles. Viral incorporation of the chimeric envelopes was demonstrated by immunoblotting virions that were pelleted from supernatant harvests of transfected TELCeB.6 cells. Figure 2 shows that the CD40 ligand (CD40L) chimeric envelopes were efficiently expressed and incorporated. Efficient incorporation of the EGF chimeric envelopes was demonstrated in a previous study. 12 Host range of chimeric vectors To demonstrate that gene transfer by the MMP-cleavable vectors was dependent upon prior exposure to endogenous MMPs, we measured their titers on cells expressing high or low levels of these proteases. For the EGF-displaying vectors the outcome of these experiments was previously reported. To summarize these data, the titer of the E.MMP.A vector was about 100-fold higher on MMP-rich HT1080 cells compared with MMP-poor A431 cells, whereas the titer of the noncleavable E.G 4 S.A vector was consistently low on both cell lines. Moreover, the titer enhancement of the E.MMP.A vector on HT1080 cells could be abrogated by the addition of MMP inhibitors. In the current study the CD40L-displaying vectors were titrated on MMP-poor A431 cells, MMP-rich HT1080 cells and on MMP-hyperexpressing HT1080 cells that had been transfected with a membrane type-1 MMP (MT1-MMP) expression plasmid. Table 1 shows that the non-cleavable (CD40L.G 4 S.A) vector gave consistently low titers on all cell lines tested whereas the titer of the MMP-cleavable CD40L-displaying vector (CD40L.MMP.A) was significantly enhanced on the MMP-expressing HT1080 cells and was further increased on the hyperexpressing MT1-MMP transfectants.
Cell mixing studies A major goal of the current study was to determine whether the MMP-activatable vectors could discriminate between MMP-rich and MMP-poor cells in a heterogeneous mixture of the different cell types. To facilitate The viral supernatants were incubated on the respective cells for 6 h in the presence of 8 g/ml polybrene at 37°C. Results are expressed as the number of cell colonies stained blue with X-gal.
these experiments GFP-expressing subclones of the HT1080 and A431 cell lines were generated so that the admixed cells could be separated by flow cytometry before X-gal staining. Equal numbers of MMP-rich and MMP-poor cell lines were fully mixed together, exposed to the EGF-displaying or CD40L-displaying vectors and then separated by flow cytometry for X-gal staining. Selective transduction of the MMP-rich cells was apparent for both the EGF-displaying (Figure 3a ) and the CD40L-displaying MMP-activatable vectors ( Figure  3b ), whereas the control vectors did not show any significant selectivity.
In vivo studies
The activities of many proteases, including MMPs, are subject to complex regulation in vivo by multiple inhibitors and activators. 19 It was therefore important to determine whether the MMP-activatable vectors would be activated by MMP-rich cells in an in vivo setting. HT1080 and A431 tumor xenografts were therefore established in nude mice and concentrated stocks of the EGF-displaying and wild-type vectors were administered by direct intratumoral inoculation. Three days later the tumors were excised, disaggregated and replated. After overnight culture the adherent cells were tested for ␤-galactosidase expression. Selective transduction of the MMP-rich HT1080-derived xenografts was apparent for the MMP- 
Discussion
We have shown in this study that MMP-activatable vectors can be used to target gene delivery to MMP-rich cells in a heterogeneous mixture of different cell types expressing a high or low abundance of membrane-associated MMPs. We have further demonstrated the in vivo potential of the protease targeting strategy by showing that the MMP-activatable vectors could selectively transduce MMP-rich tumor xenografts in nude mice.
Two different types of protease-activatable vectors were used in the current study, each displaying a different inhibitory polypeptide. EGF inhibits the entry of E.MMP.A vectors by competitively sequestering them away from the viral (RAM-1) receptors and on to EGF receptors which do not support subsequent steps leading to membrane fusion. 1 Conversely, the C-terminal domain of CD40 ligand is believed to form a trimeric cap at the tip of the viral envelope glycoprotein which sterically inhibits attachment to RAM-1 receptors. 16 In either case, the infectivity of the vectors could be fully restored by cleavage of the MMP-sensitive linker by endogenous membrane-associated MMPs on MMP-rich target cells.
In cell mixing experiments, both vectors could efficiently discriminate between MMP-rich and MMP-
Figure 4 Results of the in vivo experiment in which a concentrated preparation of the E.MMP.A, E.G 4 S.A. or 4070A vector was injected into the subcutaneous A431 or HT1080 tumor in nude mice. After 3 days, the tumors were excised, disaggregated, allowed to settle on to a tissue culture dish after which the cells were stained with X-gal.
poor cells. These results suggest that the MMP-activatable vectors must establish intimate contact with the surface of the MMP-expressing target cells before they are cleaved. Thus, commitment to a particular target cell precedes cleavage activation by the cell-associated protease.
Membrane-associated MMPs are attractive targets for cancer gene therapy since they are critical to the processes of cancer invasion and metastasis. 20, 21 Aside from the MMPs, the serine proteases of the urokinase-plasmin system 22 are also of major importance for cancer invasion and metastasis and we recently reported the development of a novel plasmin-activatable retroviral vector. 14 Protease targeting may also be of value outside the cancer gene therapy field. Membrane-associated proteases have been implicated in many cellular processes including cell motility, 23 ligand shedding 24 and receptor activation 25 and many of these proteins are known to be expressed in a tissue-specific manner. Knowledge of the substrate specificity of these alternative protease targets will be of value to guide the design of novel proteaseactivatable vectors. Alternatively, uncharacterized protease targets may be accessible through selection strategies using retrovirus display libraries presenting a diverse array of engineered substrate sequences. 17 Although C-type retroviral vectors have been used extensively in human gene therapy trials, they suffer from a number of limitations, one of the most serious being their inability to transduce quiescent cells. 26 This limitation provided the impetus for a number of groups to engineer novel lentiviral vectors from different species of lentivirus, all of which are capable of transducing quiescent cells. [27] [28] [29] In light of these developments, it is worth noting that MLV envelope glycoproteins can be pseudotyped into lentiviral vectors and the protease targeting strategies described in this study should therefore be readily transferable from C-type retroviral vectors to lentiviral vectors. Experiments to test this assumption are currently underway.
In summary, we have shown that MMP-targeted vectors can selectively transduce MMP-rich target cells in a heterogeneous population and can selectively transduce MMP-rich tumor xenografts in vivo. Protease targeted vectors have considerable appeal as vehicles for targeting gene delivery to specific protease-rich cell populations in vivo.
Materials and methods
Construction of chimeric envelope expression vectors
The construction of the E.MMP.A and E.G 4 S.A envelope expression plasmids have been described previously. 12 The CD40L-4070A chimeric vectors, CD40L.G 4 S.A, and CD40L.MMP.A, consist of the extracellular C-terminal domain of CD40L (Gly 116-Leu 261) flanked by SfiI and NotI restriction sites, linked to codon +1 of the N-terminus of the wild-type 4070A MLV SU envelope by different linkers (Figure 1 ). In the CD40L.G 4 S.A vector, CD40L is linked to the 4070A-SU via a non-cleavable AAAG 4 S linker, and in CD40L.MMP.A, via a MMP-cleavable linker (AAAPLGLWA). The SfiI-NotI PCR fragment encoding the 146 amino acids of the soluble extracellular domain of the trimeric CD40L (Gly 116-Leu 261) 30 was generated using a CD40L cDNA template (ATCC 79813; Rockland, MD, USA) and two primers (with restriction sites underlined), sCD40Lb (5Ј Ͼ CCG GTA CCG GCC CAG CCG GCC GGT GAT CAG AAT CCT CAA ATT GC) with a SfiI site and nCD40Lf (5Ј Ͼ AAG TCT TAG CGG CCG CGA GTT TGA GTA AGC CAA AGG) with a NotI site. To obtain CD40L.G 4 S.A and CD40L.MMP.A, the SfiI-NotI digested CD40L PCR fragment was cloned into SfiI-NotI digested E.G 4 S.A or E.MMP.A backbones, respectively. The sequences of the constructs were verified by DNA sequencing.
The various envelope expression plasmids were stably transfected by calcium phosphate precipitation into TELCeB.6 complementing cells which express Moloney MLV gag-pol proteins and the nlsLacZ retroviral vector. 31, 32 The transfected TELCeB.6 cells produce infectious enveloped viral particles capable of transferring the LacZ marker gene into the target cells. The transfected cells were selected in 10% FCS-DMEM containing 50 g/ml phelomycin (Sigma, Poole, UK). Resistant colonies were pooled and expanded, and before harvest, the confluent cells were transferred from 37°C to 32°C for 72 h. The viral supernatants were then harvested and filtered (0.45 m, Acrodisc; Gelman Sciences, Ann Arbor, MI, USA) after overnight incubation of the confluent cells with serum-free DMEM at 32°C. These filtered supernatants were used either for immunoblotting or infection assays.
Immunoblots
For immunoblotting, the viral particles were pelleted by ultracentrifugation of the filtered viral supernatant (Beckman, Fullerton, CA, USA) at 113 348 g for 1 h at 4°C in a SW40 rotor. The pellet was then resuspended in 100 l of phosphate-buffered saline (PBS) and stored at −70°C until further analysis. An aliquot (10 l) of the viral proteins was separated by electrophoresis on a 10% SDS-PAGE gel, electrotransfered on to nitrocellulose membrane (Hybond ECL, Amersham Life Sciences, Amersham, UK) and detected by immunostaining with goat antisera raised against Rauscher leukemia virus gp 70-SU envelope protein (Quality Biotech), followed by horseradish peroxidase (DAKO, Glostrup, Denmark) and developed using an enhanced chemiluminescence kit (Amersham).
Cell culture
The viral complementing TELCeB.6 cells, the A431 (human epithelial carcinoma; ATCC CRL1555) and HT1080 (human fibrosarcoma; ATCC CCL121) cell lines were grown in Dulbecco's modified Eagle's medium (DMEM; Gibco-BRL, Rockville, MD, USA) supplemented with 10% fetal calf serum (FCS; PAA Biologicals, Consett, UK), benzylpenicillin (60 g/ml) and streptomycin (100 g/ml) at 37°C in an atmosphere of 5% CO 2 .
Generation of HT1080 and A431 cells expressing green fluorescent protein (GFP) The HT1080 cells were transfected with a GFP expression plasmid (mGFPS65T) and clones were selected under 1 mg/ml G418 10% FCS-DMEM. The HT1080-GFP or A431-GFP cells were selected by screening for the clone of cells that showed the highest shift in fluorescence compared with the untransfected parental HT1080 or A431 cells when analyzed by FACS (FACSCalibur, Becton Dickinson, Franklin Lakes, NJ, USA).
Cell-mixing experiments
Equal numbers (2 × 10 5 cells) of A431 and HT1080-GFP cells were mixed together and grown overnight. The next day, the cells were washed once in serum-free DMEM and viral supernatant was added on to the cells for 6 h in the presence of 8 g/ml polybrene. At the end of the incubation period, the cells were washed and 10% FCS-DMEM was added. The next day, the cells were removed from the tissue culture flask with EDTA and the A431 and HT1080-GFP cells were separated by FACS sorting using a FACS StarPlus machine (Becton Dickinson). The cells were grown separately for 5 days after which they were stained with X-gal. A similar cell-mixing experiment was carried out with A431-GFP and HT1080-MT1-MMP cells infected with the CD40L.MMP.A or CD40L.G 4 S.A vectors. The number of blue colonies was counted under the microscope using a transparent grid and the result expressed as the percentage of blue colonies.
Concentration of viral stocks
The viral supernatant was harvested and filtered (0.45 m) after overnight incubation of the viral complementing TELCeB.6 cells with serum-free DMEM. Calcium chloride was added to the filtered supernatant (final concentration 10 mm) and the mixture was incubated at 37°C for 30 min. 33 The mixture was then centrifuged at 9000 g for 2 min to pellet the calcium phosphate that was formed. The supernatant was removed and EDTA was added to dissolve the pellet. The solution was then dialysed against saline for 6 h at 4°C. The concentrated viral preparation was then used for in vivo injection into tumor cells.
In vivo injection of tumor cells and viral supernatant
The A431 or HT1080 cells were injected subcutaneously (5 × 10 7 cells per site/100 l inoculum) into the flank region of athymic nude mice. The animals were examined daily until the tumor became palpable and reached a size of 0.75 cm by 0.75 cm in two perpendicular dimensions (about 24 days). The respective concentrated preparations of viral supernatant were then injected (100 l inoculum) into the tumor. After 3 days, the tumor was excised and the cells were disaggregated by passing through a metal sieve. The cells were then left to settle overnight on to a tissue culture well. The next day, the cells were stained with X-gal. The number of cells stained blue with X-gal was counted under the microscope using a transparent grid and the result expressed as the percentage of blue cells.
